| 2022-03-15 |
复牌提示：
2022-03-10 19:49:12 停牌，复牌日期 2022-03-14 00:00:01
|
| 2022-03-11 |
详情>>
内部人交易：
Aurentz Vincent等共交易35笔
|
| 2022-02-23 |
详情>>
股本变动：
变动后总股本6165.94万股
|
| 2022-02-23 |
详情>>
业绩披露：
2021年年报每股收益-10.14美元,归母净利润-6.16亿美元,同比去年增长-52.31%
|
| 2022-02-23 |
财报披露：
美东时间 2022-02-23 盘后发布财报
|
| 2022-01-03 |
股东大会：
将于2022-02-02召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated December 12, 2021 (such agreement, as it may be amended, modified or supplemented from time to time, the “Merger Agreement”), by and among Arena, Pfizer Inc., a Delaware corporation (“Pfizer”), and Antioch Merger Sub, Inc., a Delaware corporation (“Merger Sub”). Upon the terms and subject to the conditions of the Merger Agreement, Merger Sub will merge with and into Arena, with Arena continuing as the surviving corporation and a wholly owned subsidiary of Pfizer (the “Merger”).
2.To consider and vote on the proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to Arena’s named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement (the “Compensation Proposal”);
3.To consider and vote on any proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies to approve the proposal to adopt the Merger Agreement if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting (the “Adjournment Proposal”).
|
| 2021-11-04 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-7.61美元,归母净利润-4.61亿美元,同比去年增长-63.08%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-05 |
详情>>
业绩披露：
2021年中报每股收益-4.39美元,归母净利润-2.65亿美元,同比去年增长-42.88%
|
| 2021-05-05 |
详情>>
业绩披露：
2021年一季报每股收益-1.98美元,归母净利润-1.18亿美元,同比去年增长-18.17%
|
| 2021-04-27 |
股东大会：
将于2021-06-11召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees for director named herein to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal (Proposal 1);
2.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice (Proposal 2);
3.To approve the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (Proposal 3);
4.To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2021 (Proposal 4);
5.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2021-02-23 |
详情>>
业绩披露：
2018年年报每股收益-0.63美元,归母净利润-2939.9万美元,同比去年增长67.84%
|
| 2021-02-23 |
详情>>
业绩披露：
2020年年报每股收益-7.39美元,归母净利润-4.05亿美元,同比去年增长-201.81%
|
| 2020-11-09 |
详情>>
业绩披露：
2019年三季报(累计)每股收益9.78美元,归母净利润4.86亿美元,同比去年增长595.23%
|
| 2020-11-09 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-5.27美元,归母净利润-2.83亿美元,同比去年增长-158.16%
|
| 2020-08-05 |
详情>>
业绩披露：
2020年中报每股收益-3.59美元,归母净利润-1.85亿美元,同比去年增长-133.13%
|
| 2020-05-07 |
详情>>
业绩披露：
2020年一季报每股收益-2美元,归母净利润-1亿美元,同比去年增长-116.16%
|
| 2020-04-29 |
股东大会：
将于2020-06-12召开股东大会
会议内容 ▼▲
- 1.To elect the eight nominees for director named herein to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal (Proposal 1);
2.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice (Proposal 2);
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to effect an increase in the total number of authorized shares of our common stock (Proposal 3);
4.To approve the Arena Pharmaceuticals, Inc. 2020 Long-Term Incentive Plan (Proposal 4);
5.To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2020 (Proposal 5);
6.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2020-02-27 |
详情>>
业绩披露：
2019年年报每股收益7.99美元,归母净利润3.98亿美元,同比去年增长1452.27%
|
| 2019-04-30 |
股东大会：
将于2019-06-13召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees for director named herein to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal (Proposal 1);
2.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice (Proposal 2);
3.To approve an amendment and restatement of the Arena Pharmaceuticals, Inc. Amended and Restated 2017 Long-Term Incentive Plan to, among other things, increase the number of shares authorized for issuance under the Amended and Restated 2017 Long-Term Incentive Plan (Proposal 3);
4.To approve the Arena Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan (Proposal 4);
5.To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2019 (Proposal 5);
6.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2018-04-30 |
股东大会：
将于2018-06-13召开股东大会
会议内容 ▼▲
- 1.To elect the seven nominees for director named herein to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal (Proposal 1);
2.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice (Proposal 2);
3.To approve the amendment and restatement of the Arena Pharmaceuticals, Inc., 2017 Long-Term Incentive Plan to, among other things, increase the number of shares authorized for issuance under the 2017 Long-Term Incentive Plan (Proposal 3);
4.To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2018 (Proposal 4);
5.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2017-06-14 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2017-04-28 |
股东大会：
将于2017-06-13召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees for director named herein to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal (Proposal 1);
2.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice (Proposal 2);
3.To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers (Proposal 3);
4.To approve a series of alternate amendments to our Amended and Restated Certificate of Incorporation to effect, at the option of the Board of Directors, a reverse stock split of our common stock at a reverse stock split ratio ranging from one-for-six (1:6) to one-for-ten (1:10), inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board of Directors prior to the date of our 2018 Annual Meeting of Stockholders (Proposal 4);
5.To approve a series of alternate amendments to our Amended and Restated Certificate of Incorporation to effect, if and only if Proposal 4 is both approved and implemented, a reduction in the total number of authorized shares of our common stock as illustrated in the table under the caption "Effects of Authorized Shares Reduction" in the section of the accompanying proxy statement entitled "Approval of Reduction in the Number of Authorized Shares of Common Stock" (Proposal 5);
6.To approve the Arena Pharmaceuticals, Inc., 2017 Long-Term Incentive Plan (Proposal 6);
7.To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2017 (Proposal 7);
8.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2016-04-28 |
股东大会：
将于2016-06-13召开股东大会
会议内容 ▼▲
- 1.To elect the eight nominees for director named herein to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal;
2.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice;
3.To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2016;
4.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2015-04-29 |
股东大会：
将于2015-06-12召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees for director named herein to the company's Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal;
2.To approve the amendment and restatement of the Arena Pharmaceuticals, Inc., 2009 Employee Stock Purchase Plan, as amended, to, among other things, increase the number of shares of the company's common stock authorized and available for future issuance under the 2009 Employee Stock Purchase Plan, as amended, to a total of 1.5 million shares;
3.To approve, on an advisory basis, the compensation of the company's named executive officers, as disclosed in the proxy statement accompanying this notice;
4.To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as the company's independent auditors for the fiscal year ending December 31, 2015;
5.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2014-04-29 |
股东大会：
将于2014-06-13召开股东大会
会议内容 ▼▲
- 1. To elect the nine nominees for director named herein to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal;
2. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice;
3. To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2014;
4. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2013-04-29 |
股东大会：
将于2013-06-10召开股东大会
会议内容 ▼▲
- 1. To elect the nine nominees for director named herein to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal;
2. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice;
3. To approve the Arena Pharmaceuticals, Inc., 2013 Long-Term Incentive Plan;
4. To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2013;
5. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|